Eli Lilly drastically cut the price of its weight-loss drug, Mounjaro, in the Chinese market.
The monthly cost for the lowest dose fell nearly 70%. The price dropped from RMB1,758 to RMB599 on e-commerce platforms, including JD.com.
Lilly implemented the aggressive pricing strategy to respond directly to growing competition in the lucrative Chinese obesity and diabetes treatment market. The move aims to secure a stronger foothold and increase patient access as rivals, such as Novo Nordisk, vie for market share.
No specific market reaction analysis to this price cut was immediately available.